TY  - CHAP
M1  - Book, Section
TI  - Colorectal Cancer
A1  - Ursem, Carling
A1  - McQuaid, Kenneth R.
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2023
T2  - Current Medical Diagnosis & Treatment 2023
AB  - Key  Clinical  Updates  in  Colorectal  CancerFor  the  50%  of  patients  with  metastatic  CRC  who  have  KRAS/NRAS/BRAF  wild-type  tumors,  cetuximab  and  panitumumab  (monoclonal  antibodies  to  the  epithelial  growth  factor  receptor,  in  combination  with  chemotherapy,  can  extend  median  survival  by  2  to  4  months  compared  with  chemotherapy  alone.  For  the  5%  to  10%  with  BRAF  V600E  sequence  variations,  targeted  combination  therapy  with  BRAF  and  EGFR  inhibitors  extend  overall  survival  to  9.3  months,  compared  with  5.9  months  for  those  receiving  standard  chemotherapy.In  four  randomized  clinical  trials  (n  =  458,002),  intention  to  screen  with  1-  or  2-time  flexible  sigmoidoscopy  versus  no  screening  was  associated  with  a  significant  decrease  in  CRC–specific  mortality.National  Comprehensive  Cancer  Network.  https://www.nccn.org/professionals/physician_gls/pdf/colon.pdfNational  Comprehensive  Cancer  Network.  https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdfShaukat  A  et  al.  Am  J  Gastroenterol.  [PMID:  33657038]  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1193162528
ER  -